Skip to content
Screener

Operating Income at other companies

IAR
Integra LifeSciencesIART
$19.29M+104%
MiMedx Group logo
MiMedx GroupMDXG
-$18.47M-249%
SANUWAVE Health, Inc. logo
SANUWAVE Health, Inc.SNWV
-$280K-119%
Axogen logo
AxogenAXGN
-$2.16M-229%
Solventum logo
SolventumSOLV
$181M-15.4%
InfuSystem Holdings logo
InfuSystem HoldingsINFU
$1.59M+157%

Other financials

Income statement

See full
Revenue$43.8M-56.7%
Gross profit$63.0M-22.5%
Net income-$96.3M-925%
EPS (diluted)-$0.77-670%

Balance sheet

See full
Cash & equivalents$46.1M-36.9%
Total debt$36.6M+19.2%
Total equity$148.3M-36.4%
Total assets$406.4M-11.9%

Cash flow

See full
Operating cash flow-$31.7M+3.7%
CapEx$1.1M-69.8%
Free cash flow-$32.8M+10.3%

Valuation

See full
Market cap$239.33M-59.1%
Enterprise value$229.8M-57.7%
P/S0.5×-0.8×

Profitability

See full
Gross margin75.9%+0.8pp
Operating margin-7.8%
Net margin-18.4%-20.8pp
FCF margin6.9%

Returns & leverage

See full
Return on equity-44.1%-48.0pp
Debt / equity0.2×+0.1×
Current ratio3.5×-0.4×

Where this comes from

Reported directly by Organogenesis Holdings Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Organogenesis Holdings Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338049
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development18,29710,39533,45821,035
Fair value adjustment to assets held for sale(1,188)1,746(1,188)8,313
Total operating expenses94,747113,581200,866227,020
Loss from operations(50,992)(12,576)(119,883)(39,322)
Other income, net:
Interest income, net1386695181,630
Other income (expense), net(26)731275
Total other income, net1127425301,705

Item 1. Unaudited Condensed Consolidated Financial Statements.

FAQ

What is Organogenesis Holdings Inc.'s operating income?
Organogenesis Holdings Inc. (ORGO) reported operating income of -$50.99M in Q2 2026.
How has Organogenesis Holdings Inc.'s operating income changed year-over-year?
Organogenesis Holdings Inc.'s operating income decreased by 305.5% year-over-year, from -$12.58M to -$50.99M.
What is the long-term trend for Organogenesis Holdings Inc.'s operating income?
Over 2 years (2021 to 2025), Organogenesis Holdings Inc.'s operating income has grown at a -21.3% compound annual growth rate (CAGR), from $72.22M to $44.69M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Organogenesis Holdings Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude